Drug intelligence / Profile preview

MTLH-001

Development stage: Preclinical
Lead developer: WuXi MTLH Biotechnology
Modality: Peptides

Overview

MTLH-001 is an anti-cancer drug developed by WuXi MTLH Biotechnology. It is a peptide-based antagonist of the Platelet-derived growth factor receptor (PDGFR). At the time of a licensing deal, it was in pre-clinical development. WuXi MTLH Biotechnology out-licensed the China rights for MTLH-001 to Shanghai The First Biochemical Pharmaceutical Co. Ltd., a subsidiary of Shanghai Pharmaceutical Group, with a co-development agreement to meet FDA standards and support a global launch, while WuXi MTLH retained rights outside of China.

Targets

PDGFR (PDGFR family)

Beyond the preview

Go deeper on MTLH-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MTLH-001.

Explore the full profile